Rexulti Kit
NDC Package 59148-044-14
Package Information
Rexulti (brexpiprazole) kits is rEXULTI is indicated for:Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adultsTreatment of schizophrenia in adults and pediatric patients ages 13 years and olderTreatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use:REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3)]. This formulation utilizes a kit delivery system. Marketed by Otsuka America Pharmaceutical, Inc., this product is identified by NDC 59148-044 and is authorized under FDA application NDA205422.
Identification & Billing
- RxCUI: 1658319 - brexpiprazole 0.25 MG Oral Tablet
- RxCUI: 1658325 - REXULTI 0.25 MG Oral Tablet
- RxCUI: 1658325 - brexpiprazole 0.25 MG Oral Tablet [Rexulti]
- RxCUI: 1658325 - Rexulti 0.25 MG Oral Tablet
- RxCUI: 1658327 - brexpiprazole 0.5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59148 - Otsuka America Pharmaceutical, Inc.
- 59148-044 - Rexulti
- 59148-044-14 - 1 KIT in 1 CARTON * 7 TABLET in 1 BLISTER PACK * 7 TABLET in 1 BLISTER PACK
- 59148-044 - Rexulti
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59148-044-14 identifies a specific commercial package of 1 kit in 1 carton * 7 tablet in 1 blister pack * 7 tablet in 1 blister pack of Rexulti, a human prescription drug labeled by Otsuka America Pharmaceutical, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Otsuka America Pharmaceutical, Inc. on July 10, 2015. The current certification is valid through December 31, 2027.
How is this Otsuka America Pharmaceutical, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59148004414. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.